The global radiopharmaceuticals market is on the brink of transformative growth, driven by substantial investments and cutting-edge scientific breakthroughs. According to a recent report by Future Market Insights (FMI), the market is projected to achieve a valuation of USD 6,972.1 million by 2024, with an impressive compound annual growth rate (CAGR) of 3.40% anticipated from 2024 to 2034. By the end of the forecast period, the market is expected to exceed USD 11,635 million.
This robust growth trajectory underscores the expanding role of radiopharmaceuticals in contemporary healthcare. These advanced therapeutic and diagnostic agents are revolutionizing the early detection and treatment of various diseases, including cancer and cardiovascular conditions. The increasing demand for precision medicine and advanced diagnostic tools is propelling the radiopharmaceuticals sector forward, positioning it as a cornerstone of modern medical innovation.
Radiopharmaceuticals, which combine radioactivity with pharmaceuticals to target specific tissues, are becoming indispensable in delivering accurate diagnostics and tailored therapies. Their application is crucial in improving patient outcomes through early disease detection and effective treatment strategies. As the healthcare landscape evolves and the need for advanced medical solutions grows, radiopharmaceuticals are set to play a pivotal role in shaping the future of patient care.
The FMI report highlights a promising outlook for the industry, reflecting the ongoing advancements in radiopharmaceutical technology and its increasing integration into clinical practice. The market’s growth is indicative of a broader trend towards precision medicine and personalized healthcare, driven by scientific innovation and rising patient expectations.
Key Market Insights:
North America is leading the radiopharmaceuticals market, driven by the high prevalence of cardiovascular diseases and cancer. The region’s dominance is expected to continue, supported by advancements in radioisotope production methods for chronic disorder treatments.
Europe, particularly the UK, holds a significant market share due to high cancer incidence rates. According to Cancer Research UK, the UK alone has 367,167 cancer patients, contributing to the region’s substantial market presence.
Asia-Pacific is forecasted to experience notable growth, with new product launches, collaborations, and distribution agreements driving the market forward.
“The broad application of radiopharmaceuticals as biomarkers in molecular imaging is expected to significantly impact the market in the coming years,” says an analyst from Future Market Insights.
Competitive Landscape:
- GE Healthcare has partnered with NorthStar Medical Radioisotopes, LLC to produce and distribute iodine-123 (I-123) capsules across the US.
- Bracco Diagnostics Inc. has launched the ‘Bracco Mobile Isotope Service’ in collaboration with CardioNavix, LLC to enhance patient access to cardiac PET imaging.
- Jubilant Radiopharma signed an MoU with Navidea Biopharmaceuticals for the exclusive distribution of ‘Tilmanocept’ in the Americas.
- Bayer AG announced its acquisition of Noria Therapeutics Inc. and PSMA Therapeutics Inc. to expand its oncology portfolio.
- Norgine B.V. acquired Azanta A/S, adding Nimorazole and Angusta to its product line.
- Curium acquired MAP Medical to strengthen its European footprint.
- The US FDA approved Gallium 68 PSMA-11 (Ga 68 PSMA-11) as the first PET imaging drug for diagnosing prostate cancer in December 2020.
Radiopharmaceutical Insights in High Demand: Access Our Comprehensive Report for Key Trends and Information!
Key Companies in the Market:
- Bayer AG
- Bracco Imaging S.p.A.
- Cardinal Health, Inc.
- Eli Lilly and Company
- Curium Pharma
- Lantheus Holdings, Inc.
- Novartis AG
- Nordion (Canada) Inc.
- Jubilant Radiopharma
Market Segments:
By Radioisotope Type: Technetium-99, Fluorine-18, Iodine-131, Lutetium-177, Yttrium-90, Gallium-68, Gallium-67, Rubidium-82, Iodine-123, Iodine-125, Indium-111, Others.
By Application: Oncology, Cardiology, Gastroenterology, Neuroendocrinology, Neurology, Nephrology, Others.
By Source: Cyclotrons, Nuclear Reactors.
By End User: Hospitals, Diagnostic Imaging Centers, Ambulatory Surgical Centers, Cancer Research Institutes.
By Region: North America, Latin America, Europe, Asia-Pacific, Middle East and Africa (MEA).
As the radiopharmaceuticals sector continues to evolve, staying updated with the latest developments and trends is crucial. For more insights and detailed reports, follow the latest updates from Future Market Insights.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
